Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Unveiling the Molecular Secrets of Reproductive Mood Disorders: a Multi-Omics Approach Project

Project description

Uncovering the biological basis of reproductive mood disorders

Reproductive mood disorders (RMDs) including premenstrual disorder and postpartum depression significantly affect women’s mental health. Diagnosis and treatment remain challenging. Linked to hormonal changes, RMDs also likely involve genetic, inflammatory and metabolic factors. The ERC-funded MoodMAP project seeks to uncover molecular markers for RMDs and the biological basis of vulnerability to enhance diagnostics, prevention and treatment. Using Nordic cohort data, MoodMAP will integrate genomic, proteomic and metabolomic analyses, explore biomarkers via hormone-manipulated cells and apply machine learning and multiomics to predict treatment outcomes. By studying the two RMDs with laboratory, epidemiological and statistical methods, MoodMAP aims to better understand sex hormone-related sensitivity to mood disorders.

Objective

Reproductive mood disorders (RMDs), including premenstrual disorder and postpartum depression, have a significant impact on women and their families, contributing to the well-known gender gap in mental health. However, effectively diagnosing and treating RMDs remains an ongoing challenge. These conditions are closely tied to hormonal changes during menstruation and childbirth, indicating a shared vulnerability. While the precise mechanisms are not yet fully understood, emerging data, including my work, supports the hypothesis that genetic predisposition, chronic inflammation, and metabolic dysfunction play pivotal roles in the development of RMDs. The MoodMAP project aims to discover novel molecular markers for RMDs, provide insights into the biological factors influencing varying vulnerabilities to mood disorders in women, and enhance diagnostic, preventative, and treatment strategies for RMDs. The endeavor leverages three Nordic population-based cohorts a) to DEPICT a comprehensive architecture of RMDs by integrating genomic, inflammatory proteomic, and metabolomic data; b) to TRIANGULATE evidence for identifying biologically functional and causal biomarkers using cell data manipulated with hormones and advanced epidemiologic methods; c) and to PREDICT treatment outcomes, including treatment resistance and subsequent suicidal behavior, through multi-omics data and machine-learning methods. MoodMAP adopts an innovative approach by studying both RMDs together, aiming to uncover the biological basis of female vulnerability to mood disorders through multi-omics data. By integrating advanced omics techniques, hormone-manipulated cell data, and cutting-edge epidemiologic and statistical methods, MoodMAP holds the potential to understand the psychiatric sensitivity associated with sex hormones, drive transformative changes of diagnosis, prevention, and treatment strategies for RMDs, and ultimately contribute to the reduction of the gender gap in mental health.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-STG

See all projects funded under this call

Host institution

KAROLINSKA INSTITUTET
Net EU contribution
€ 1 499 999,00
Address
NOBELS VAG 5
171 77 STOCKHOLM
Sweden
Region
Östra Sverige Stockholm Stockholms län
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 499 999,00

Beneficiaries (1)